Wednesday 11 June 2008
Morning Sessions 8.15 – 10.30am
W1: Physiological testing interpretation
Hall tbc
Dr R Crapo (USA) Dr M Miller (UK)Dr B Cooper (UK)
W2: Expert discussion on smoking cessation
Hall tbc
Dr G Wesseling (NL) Dr P Tonnesen (Den) Open debate
W3: Nasal ventilation in COPD
Hall tbc
8.15 NIV for COPD acute and chronic - patient selection, the evidence
Dr M Elliott (UK)
8.45 Interfaces
Mr M Latham (UK)
9.15 Setting the ventilator and troubleshooting
- how does an understanding of physiology help
Dr P Navalesi (Italy)
9.55 Panel discussion
W4:
Hall tbc
Part 1: Developing the skills of the multidisciplinary team
Prof S Hill (UK)K Walker (UK)
Part 2: Developing the expert patient
Dame H Shovelton (UK)
10.30 – 11.00am Refreshment Break
Hall 3 11.00 – 1.00pm
PS1: OPENING PLENARY
Hall 1
Management of the COPD patient 1 -what clinical trials are telling us
Chairpersons: Prof P Calverley (UK) & Prof S Rennard (USA)
11.00 Welcome
11.05 Mortality and co-morbid conditions
Prof S Rennard (USA)
11.25 Exacerbations, their treatment, and pneumonia
Prof J A Wedzicha (UK)
11.45 Lessons from alpha-1 antitrypsin augmentation Prof A Dirksen (Den) Prof R Stockley (UK)12.25 Do we have adequate models of COPD? Prof G Anderson (Aus)12.45 Presentation of Lifetime Achievement Awards 1.00 – 2.00pm Lunch and Poster Viewing Hall 3
Wednesday 11 June 2008 Afternoon Sessions 2.00 – 3.30pm PS2: Management of the COPD patient 2 – Impact of co-morbidities Hall 1Chairperson: Prof L Fabbri (Italy)2.00 What is the clinical evidence? Prof L Fabbri (Italy)2.20 What are the genetics of co-morbidity Prof R Stockley (UK) 2.40 COPD and vascular disease Prof E Wouters (NL)3.00 COPD and osteoporosis Prof D Shale (UK)3.20 Implications for management Panel discussion 3.30 – 4.00pm Refreshment Break Hall 3 4.00 – 5.30pm SS1: Patient focused outcomes - how should we measure and validate them Hall tbcChairpersons: Prof P Meek (USA) & Prof S Hill (UK)4.00 Concept of patient focused outcomes Prof P Meek (USA)4.15 Measurement & validation, concepts, where we've got it right and where we need to go Prof P Jones (UK)4.30 Functional status and symptoms-why we measure them pros/cons of measurement S Lareau (USA) 4.45 How can we validate self management strategies? Prof M Partridge (UK)5.00 Exacerbation outcomes Prof R Stockley (UK)5.15 Discussion SS2: Patient phenotyping – implications for genetic studies and treatment Hall tbcChairpersons: Prof D Lomas (UK) & Dr E Silverman (USA)4.00 The role of IOS in COPD Prof P Calverley (UK)4.20 CT phenotypes of COPD Dr D Parr (UK)4.40 Sputum analysis in COPD Dr I Pavord (UK)5.00 Genetic analysis and sub-phenotypes of COPD Dr E Silverman (USA) SS3: Pathophysiology 2008 update Hall tbcChairpersons: Prof A Agusti (Spain) & Prof W MacNee (UK)4.00 Inflammation: structure-function relationships Prof J Hogg (Canada)4.20 Mechanisms of enhanced inflammation Prof W MacNee (UK)4.40 Mechanisms of persistence of inflammation Prof A Agusti (Spain)5.00 Overview: a lung maintenance programme Prof N Voelkel (USA) 5.45 – 6.45pmMajor Sponsors Symposium BI/Pfizer Symposium Hall 1 Earlier intervention in COPD: rationale and benefitsChairman: Dr C Vogelmeier (Germany) 5.45 Welcome and brief introduction to the natural history and burden of COPD Dr C Vogelmeier (Germany) 6.00 Can we impact the clinical course of COPD? Dr C Cooper (USA) 6.20 Earlier intervention in COPD – why wait? Prof M Decramer (Belgium) 6.40 Questions, summary and close Thursday 12 June 2008 Morning Sessions 8.00 – 10.00am PS3: Acute care - Exacerbations Hall 1Chairpersons: Prof J A Wedzicha & Prof F Martinez8.00 Etiology of COPD exacerbations Prof A Papi (Italy)8.30 Mechanisms of inflammation in COPD exacerbations Prof Peter Barnes (UK)9.00 Experimental models of COPD exacerbations Dr P Mallia (UK)9.30 Novel approaches to prevention of COPD exacerbations Prof J A W Wedzicha (UK) 10.00 – 10.30am Refreshment Break Hall 3 10.30 – 12.00 noonSS4: End of life care for COPD – a new approach? Hall tbcChairpersons: Dr M Morgan (UK) & S Prigmore (UK)10.30 Definition of End of life Dr N O'Kelly (UK)10.45 Patient needs Dr P White (UK)11.00 Palliative treatment options Prof S Ahmedzai (UK)11.15 Withholding, withdrawal, ceilings of treatment Dr A Simonds (UK)11.30 Liverpool End of Life care pathway Dr L Davies (UK) SS5: Role of antibiotics for both prophylaxis and therapeutic use Hall tbcChairpersons: Dr R Wilson (UK) & Prof F Blasi (Italy)10.30 Does a “bronchiectasis-like” vicious circle operate in COPD? Dr R Wilson (UK)10.50 Antibiotic prophylaxis in COPD (including the PULSE study) Dr M Miravitlles (Spain)11.10 Antibiotic trials in COPD: placebo or superiority design? Prof F Blasi (Italy)11.30 Are macrolides the answer for COPD? Prof J A Wedzicha (UK) SS6: Muscle loss in COPD, reactive or causative? Hall tbcChairpersons: Prof M Polkey (UK) & Prof M Decramer (Belgium)10.30 Overview and scope of the problem Prof M Polkey (UK)10.50 Muscle strength and daily activity Prof M Decramer (Belgium)11.10 Signaling pathways that mediate skeletal muscle atophy Dr David Glass (USA)11.30 Nutritional strategies for muscle weakness Prof A Schols (NL) 12.00 – 1.00pm Meet the ExpertsNursing research – is it practical, what does it need to focus on Prof P Meek (USA)Selection for transplantation and management Prof P Corris (UK)Bronchiectasis and COPD : the chronically colonised patient Dr R Wilson (UK)Research funding – practical advice on applying to MRC, BLF, Wellcome Prof E Chilvers (UK) 1.00 – 2.00pm Lunch and Poster Viewing Hall 3
Thursday 12 June 2008 Afternoon Sessions 2.00 – 4.00pm PS4: Chronic care - Getting the patient going Hall 1Chairpersons: Prof J A Wedzicha (UK) & Prof M Decramer (Belgium) 2.00 Rationale Prof M Decramer (Belgium) 2.15 Activity, co-morbidities and rehabilitation Prof T Troosters (NL) 2.35 Pulmonary Rehabilitation and exacerbation – when is the right time to intervene Prof M Polkey (UK) 2.55 Who should instigate rehabilitation? Prof R Jones (UK) 3.15 Questions “Tim Griffiths Memorial Lecture” 3.30 Introduction Adjuncts to rehabilitation Prof R Casaburi (USA) 4.00 – 4.30pm Refreshment Break Hall 3 4.30 – 6.00pmSS7: Standards for COPD care – can we get them into practice Hall tbcChairpersons: Prof S Hill (UK) & Prof S Buist (USA)4.30 What do we need standards for and what can we learn? Prof S Buist (USA)4.50 Establishing national standards Prof S Hill (UK) 5.10 Do guidelines help? Prof P Calverley (UK)5.30 How can standards be monitored? Prof M Pearson (UK) SS8: Practically reducing mortality in COPD; what is science telling us Hall tbcChairpersons: Prof F Martinez (USA) & Dr M Miller (UK)4.30 FEV1 and mortality Dr M Miller (UK)4.50 Treatments that reduce mortality Prof B Celli (USA)5.10 Why treatment reduces mortality Prof F Martinez (USA)5.30 Smoking cessation Prof S Rennard (USA) SS9: Realising the benefits of new therapeutic developments Hall tbcChairpersons: Prof P Barnes (UK) & Dr T Hansel (UK)4.30 How should new anti-inflammatory drugs for COPD first be tested in man ? Dr T Hansel (UK)4.50 Novel antioxidants – where are they when we need them? Prof W MacNee (UK)5.10 Reversing steroid resistance – a new approach Prof P Barnes (UK)5.30 Antiproteases – why has it taken so long? Prof R Stockley (UK)
Friday 13 June 2008 7.45 – 8.45am Meet the ExpertsPractical considerations of oxygen assessment & therapy C Mikelsons (UK)Alpha one anti-trypsin deficiency – where are we now? Prof R Stockley (UK)Sleep in COPD Dr B Cooper (UK)Nursing – open discussion S Prigmore (UK) 9.00 – 10.30SS10: Helping you to help your COPD patient Hall tbcChairpersons: Prof D Price (UK) 9.00 Models of improving practice management of COPD Dr J Cleland (UK)9.20 Software tools to assist in assessing the patient with COPD Dr R Jones (UK)9.40 Helping physicians with virtual COPD reviews Prof D Price (UK)10.00 Using the web and other self-help tools to assist in COPD management Dr Rob Horne (UK) SS11: Differential diagnosis Hall tbcChairperson: Prof R Stockley (UK)9.00 Causes of breathlessness – a clinical algorithm Prof Paul Corris (UK)9.20 How should we characterise COPD and prevent misdiagnosis Prof W MacNee (UK)9.40 Early detection & management of malignancy in COPD Prof S Spiro (UK)10.00 Does phenotype influence management? Prof B Celli (USA) SS12: Lung protection / repair – can it be done? Hall tbcChairpersons: Prof G Anderson (Aus) & Prof S Rennard (USA)9.00 Animal models – role of TNFa Dr A Churg (USA)9.20 Why doesn’t anti-TNFa work? Prof S Rennard (USA)9.40 Retinoic acid receptor g Prof G Anderson (Aus)10.00 Repair strategy Dr J Stolk (NL) 10.30 – 11.00am Refreshment Break Hall 1 Foyer 11.00 – 1.00pmPS5: FINAL INTERACTIVE PLENARY Hall 1Practicalities, barriers and opportunities in delivering COPD care 11.00 What is epidemiology telling us? Prof S Buist (USA) 11.30 Primary care perspective Prof D Price (UK) 11.40 Role of the specialist – achieving integration Prof B Celli (USA) 11.50 Can we get self-management strategies right? Prof M Partridge (UK) 12.00 Can we / should we introduce screening for the missing millions? Prof P Calverley (UK) 12.10 Interactive discussion with audience V Parry 12.50 Closing Remarks Prof S Hill (UK) & Prof R Stockley (UK)
